Mylan Comments on Teva's Agreement to Acquire Allergan's Generic Drug Unit
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/22/2026
- Nasdaq notches record-high close, AI optimism reignites and Treasury yields retreat
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Oil price dips to $100 on hopes of US-Iran diplomacy, partial recovery in Saudi exports
- Paramount, Warner Bros jump on report of settlement progress in merger fight
- Investors may be underpricing how far rate hikes could go, Deutsche says
- Pennsylvania measles cases near 800 as outbreak grows
- A timeline of Trump administration moves to weaken endangered species protections
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Nasdaq notches record-high close, AI optimism reignites and Treasury yields retreat
- SpaceX and Tesla’s AI linkup is getting deeper. Here’s what Morgan Stanley sees
Canaccord Genuity Raises Price Target on Teva Pharma (TEVA) Following Announced Acquisition of Allergan Generics
July 28, 2015 9:23 AM EDTCanaccord Genuity maintained a Hold rating on Teva Pharma (NYSE: TEVA), and raised the price target to $79.00 (from $63.00), following the announced acquisition of Allergan Generics for $40.5B - $33.75B in cash and $6.75B in stock. Analyst Corey Davis said that this is not a good signal about the overall future of the... More
Leerink Partners Raises Price Target to $84 on Teva Pharma (TEVA) Following Call with CFO
July 28, 2015 8:12 AM EDTLeerink Partners reiterated an Outperform rating on Teva Pharma (NYSE: TEVA), and raised the price target to $84.00 (from $74.00), following a call with CFO Eyal Desheh. The TEVA-AGN deal is estimated to close in 1Q'16 and management still anticipates holding its annual guidance... More
Mylan's (MYL) Price Target Reduced to $65 at Deutsche Bank
July 27, 2015 2:34 PM EDTDeutsche Bank maintained a Buy rating on Mylan (NASDAQ: MYL) but cut its price target to $65.00 (from $82.00). The change reflects standalone valuation after Teva Pharma (NYSE: TEVA) earlier withdrew its agreement to acquired the company.
"Following TEVAs announced plan to acquire Allergan... More
Teva Pharma (TEVA) PT Raised to $74 at Maxim Group on Deal for Allergan's Generic Drug Business
July 27, 2015 11:10 AM EDTMaxim Group analyst Jason Kolbert reiterated a Buy rating and raised his price target on Teva Pharma (NYSE: TEVA) to $74.00 (from $64.00) after the company agreed to acquire Allergan's legacy Actavis global generics business. The company is dropping its bid for... More
Cowen Downgrades Mylan (MYL) to Market Perform
July 27, 2015 7:50 AM EDTCowen downgraded Mylan (NASDAQ: MYL) from Outperform to Market Perform.
For an analyst ratings summary and ratings history on Mylan click here. For more ratings news on Mylan click here.
Shares of Mylan closed at $65.94 yesterday.
... MoreMylan (MYL) Comments on Teva/Allergan Deal; Strategic Focus Remains Unchanged
July 27, 2015 6:43 AM EDTMylan (Nasdaq: MYL) issued the following statement regarding Teva's (NYSE: TEVA) announcement of its entry into an agreement to acquire Allergan's (NYSE: AGN) Generic Drug Unit and its withdrawal of its unsolicited expression of interest to acquire Mylan.
Mylan... More
